SLC5A2 and diabetic kidney disease: SGLT2 inhibitors (SGLT2i), such as dapagliflozin, are universally recommended as first-line therapeutic agents in DKD treatment, supported by large-scale studies demonstrating cardiac and renal benefits (26–29).